Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Sejahteraraya Anugrahjaya Tbk (SRAJ.JK)
Tangerang, ID
PT Sejahteraraya Anugrahjaya Tbk is an Indonesian enterprise dedicated to providing medical care. Its business model is structured around two core divisions: inpatient treatment alongside its ancillary services, and outpatient consultations complete with their related infrastructure. The organization oversees a network of medical facilities operating under the Mayapada Hospital brand. Initially incorporated as PT Sejahtera Raya Anugrah in 1991, the entity formally adopted its present designation, PT Sejahteraraya Anugrahjaya Tbk, in December 1992. This Indonesian firm maintains its principal office in Tangerang and functions as a controlled entity within the PT Surya Cipta Inti Cemerlang group.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +4.50% | -7.48% | -12.97% | -16.87% | -15.61% | +361.09% | +2,058.91% | +8,603.13% | +4,018.55% | +8,721.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-17.8% Q1'26: -19.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-732.1% Q1'26: -217.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-9.7% Q1'26: -32.6% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+4.0% Q1'26: -1.1% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+2.5% Q1'26: -0.5% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+1.7% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×9.68× Q1'26: 68.03× (vs Q1'25)
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
2.59T
est: 3.48T (-25.7%)
|
4.53T
4.53T – 4.53T
+30.0% YoY
|
5.34T
5.34T – 5.34T
+18.0% YoY
|
| EBITDA |
484.61B
est: 578.64B (-16.3%)
|
752.42B
752.42B – 752.42B
+30.0% YoY
|
887.82B
887.82B – 887.82B
+18.0% YoY
|
| EBIT |
103.36B
est: 227.62B (-54.6%)
|
295.98B
295.98B – 295.98B
+30.0% YoY
|
349.24B
349.24B – 349.24B
+18.0% YoY
|
| Net Income |
-199.00B
est: -85.42B (-133.0%)
|
-56.13B
-56.13B – -56.13B
+34.3% YoY
|
74.43B
74.43B – 74.43B
+232.6% YoY
|
| SGA |
854.93B
est: 602.25B (+42.0%)
|
783.12B
783.12B – 783.12B
+30.0% YoY
|
924.04B
924.04B – 924.04B
+18.0% YoY
|
| EPS |
-16.31
est: -7.00 (-133.0%)
|
-4.60
-4.60 – -4.60
+34.3% YoY
|
6.10
6.10 – 6.10
+232.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arie Farisandi | Corporate Secretary | — | — |
| Arif Mualim | Operational Director | — | male |
| Handoko Gunawan | Head of Internal Audit | — | male |
| Navin Sonthalia | President Director | — | male |
| Victoria Tahir | Director of Finance | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRAJ.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
